Omenn said that, after a years leave providing opportunities to delve more deeply into life sciences development and science and health policy issues, he intends to take up a faculty role at the University.
The EVPMA was a new position at the University and Gil helped to define it, outgoing President Lee C. Bollinger said. He has devoted himself entirely to the University and to the Health System, a massive undertaking given the scope of our medical center. We are indebted to him for his dedication and his contributions.
Bollinger noted that Omenn has achieved many critical objectives for which the position was created and he was recruited in 1997:
Gil has been rigorous and energetic, especially in enhancing the academic core of the Medical School and in strengthening its academic focus, Bollinger said. In addition, the Health Systems financial stability is a significant accomplishment for which Gil deserves great credit and our thanks. And, of course, he has represented the University as a national spokesperson on important current issues including health care and the life sciences.
I am proud to have been President Bollingers first recruit, Omenn said. It has been a pleasure to be working so closely with so many able colleagues on the faculty and staff of the Health System, throughout the University and in the larger community. I have learned a lot and given maximal effort.
This is a full-immersion position. I am delighted to continue working to achieve the major objectives we share during the transitional leadership under Joe White as interim president. Then I will welcome the opportunity to really delve into scientific and policy problems of great interest to me.
Omenn, who also holds the title of professor of internal medicine, human genetics and public health, was appointed EVPMA in September 1997. He came to the U-M from the University of Washington, where he served as dean of the School of Public Health. He was associate director of the White House Office of Science and Technology Policy and the Office of Management and Budget during the Carter administration, and was chairman of the Presidential/Congressional Commission on Risk Assessment and Risk Management in 199497.
Omenn was a National Institutes of Health Research Career Development Awardee, a Howard Hughes Medical Institute Investigator, and founding director of the Robert Wood Johnson Clinical Scholars Program at the University of Washington. His research has involved the chemoprevention of cancers, genetic predisposition to environmental and occupational health hazards, and application of genetic concepts and protein, DNA, and pharmacogenetic techniques to the brain. Other interests include health promotion for older adults, science-based risk analysis and the ethical, legal and public health policy aspects of genetics.
Omenn holds a B.A. degree from Princeton, an M.D. from Harvard and a Ph.D. in genetics from the University of Washington.